Aptar Launches CARDAMYST Nasal Spray to Address Needs of 2 Million PSVT Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy ATR?
Source: Businesswire
- New Drug Launch: Aptar's Bidose Liquid Nasal Spray System successfully delivers the FDA-approved CARDAMYST nasal spray, aimed at treating paroxysmal supraventricular tachycardia (PSVT), which leads to 40,000 to 120,000 hospitalizations annually, marking the company's expansion into cardiovascular drug delivery.
- Market Demand: With approximately 2 million people diagnosed with PSVT in the U.S., Aptar's launch of CARDAMYST addresses this significant market need, expected to substantially enhance the company's share in the nasal drug delivery market.
- Collaborative Innovation: Aptar's close collaboration with Milestone Pharmaceuticals has resulted in a patient-friendly dual-container system that ensures reliable drug access at critical moments, further solidifying Aptar's leadership in drug delivery technology.
- Strategic Implications: The launch of CARDAMYST not only showcases Aptar's innovative capabilities in drug delivery solutions but also lays the groundwork for future expansions into other therapeutic areas, aligning with the company's long-term growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 123.360
Low
133.00
Averages
145.33
High
156.00
Current: 123.360
Low
133.00
Averages
145.33
High
156.00
About ATR
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Wall Street Rating Updates on Friday
- Nvidia Rating Reaffirmed: Wolfe maintains Nvidia as an outperform, stating that with the stock priced at just 13x their bull case EPS, it is too cheap to ignore, potentially attracting more investor interest.
- Arm Upgrade: HSBC upgrades Arm from reduce to buy, highlighting its strong positioning in the AI sector, suggesting that its transition to a major AI server CPU player presents a significant undervaluation opportunity for investors.
- Apple App Store Revenue Slowdown: Morgan Stanley reiterates Apple as overweight, noting that App Store revenue growth decelerated to 6% YoY in Q1 2023, falling short of the expected 8%, indicating market caution regarding Apple's future growth prospects.
- Oneok Upgrade: Jefferies upgrades Oneok from hold to buy, citing tangible upside potential in the current market environment, particularly as geopolitical tensions in the Middle East raise crude oil price risks.
See More
AptarGroup Appoints Gael Touya as New CEO Effective September 2026
- Leadership Transition: AptarGroup has announced that Gael Touya will succeed Stephan B. Tanda as CEO effective September 1, 2026, with Tanda remaining as an advisor to ensure a smooth transition, highlighting the company's focus on future growth.
- Strategic Growth: With over 30 years at Aptar, Gael has driven 82% revenue growth as President of Aptar Pharma, showcasing his leadership in drug delivery, and will continue to expand strategies in consumer markets.
- Operational Efficiency: Under Gael's leadership, Aptar Pharma has integrated technologies and services to enhance customer efficiency from early development to commercialization, strengthening the company's competitive position in the global drug delivery market.
- Sustainability Commitment: During Stephan's tenure, Aptar's adjusted EBITDA margins increased from 19% in 2017 to 22% in 2025, alongside significant advancements in sustainability, reflecting the company's commitment to environmental responsibility.
See More
Aptar Supports LTR Pharma's Intranasal Therapy Development
- Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
- First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
- Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
- Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
See More
River Road Acquires Significant Stake in AptarGroup
- New Investment Position: River Road Asset Management disclosed on February 24, 2026, in an SEC filing that it acquired 917,670 shares of AptarGroup, valued at $111.92 million, indicating confidence in the company's future prospects.
- Ownership Proportion Analysis: This transaction represents 1.23% of River Road's 13F reportable assets under management as of December 31, 2025, suggesting that AptarGroup is no longer among the fund's top five holdings, which may affect its risk profile.
- Market Performance Review: As of February 28, 2026, AptarGroup's shares traded at $143.71, down 1.32% over the past year, underperforming the S&P 500 by 18.68 percentage points, reflecting market caution regarding its growth potential.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which may attract environmentally-conscious investors despite its current stock performance.
See More
River Road Asset Management Acquires AptarGroup Shares Worth $111.92 Million
- New Investment Position: River Road Asset Management disclosed in an SEC filing dated February 24, 2026, that it acquired 917,670 shares of AptarGroup valued at $111.92 million, marking a new investment position that reflects confidence in AptarGroup's future growth potential.
- Asset Management Proportion: This acquisition represents 1.23% of River Road's 13F reportable assets as of December 31, 2025, indicating a strategic consideration in diversifying its investment portfolio, which could enhance overall investment returns.
- Performance Growth Outlook: AptarGroup reported a 14% increase in sales in its fourth-quarter report for 2025, with all core segments showing growth, demonstrating the company's competitiveness and sustained profitability, which is likely to attract more investor interest going forward.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which appeals to environmentally conscious investors and further enhances its market attractiveness.
See More
Consumer Staples Sector Overbought Warning
- Overbought Signals: As of February 27, 2026, Darling Ingredients Inc (NYSE:DAR) and Coca-Cola Consolidated Inc (NASDAQ:COKE) are flagged as overbought stocks in the consumer staples sector, with RSI indicators exceeding 70, indicating potential price correction risks in the short term, prompting caution among investors.
- RSI Indicator Insights: The Relative Strength Index (RSI), a momentum indicator that compares the strength of stock price increases to decreases, assists traders in assessing short-term performance, and an overbought condition may lead to losses for investors buying at high levels.
- Market Reaction: The emergence of overbought signals may prompt investors to reassess the investment value of these two stocks, potentially leading to short-term capital outflows that could affect overall market sentiment and price movements.
- Investment Strategy Adjustments: Given the current overbought conditions, investors may need to adjust their strategies, considering more attractive buying opportunities during price corrections to mitigate potential risks and optimize their portfolios.
See More
Key Wall Street Rating Updates on Friday
- Nvidia Rating Reaffirmed: Wolfe maintains Nvidia as an outperform, stating that with the stock priced at just 13x their bull case EPS, it is too cheap to ignore, potentially attracting more investor interest.
- Arm Upgrade: HSBC upgrades Arm from reduce to buy, highlighting its strong positioning in the AI sector, suggesting that its transition to a major AI server CPU player presents a significant undervaluation opportunity for investors.
- Apple App Store Revenue Slowdown: Morgan Stanley reiterates Apple as overweight, noting that App Store revenue growth decelerated to 6% YoY in Q1 2023, falling short of the expected 8%, indicating market caution regarding Apple's future growth prospects.
- Oneok Upgrade: Jefferies upgrades Oneok from hold to buy, citing tangible upside potential in the current market environment, particularly as geopolitical tensions in the Middle East raise crude oil price risks.
See More
AptarGroup Appoints Gael Touya as New CEO Effective September 2026
- Leadership Transition: AptarGroup has announced that Gael Touya will succeed Stephan B. Tanda as CEO effective September 1, 2026, with Tanda remaining as an advisor to ensure a smooth transition, highlighting the company's focus on future growth.
- Strategic Growth: With over 30 years at Aptar, Gael has driven 82% revenue growth as President of Aptar Pharma, showcasing his leadership in drug delivery, and will continue to expand strategies in consumer markets.
- Operational Efficiency: Under Gael's leadership, Aptar Pharma has integrated technologies and services to enhance customer efficiency from early development to commercialization, strengthening the company's competitive position in the global drug delivery market.
- Sustainability Commitment: During Stephan's tenure, Aptar's adjusted EBITDA margins increased from 19% in 2017 to 22% in 2025, alongside significant advancements in sustainability, reflecting the company's commitment to environmental responsibility.
See More
Aptar Supports LTR Pharma's Intranasal Therapy Development
- Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
- First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
- Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
- Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
See More
River Road Acquires Significant Stake in AptarGroup
- New Investment Position: River Road Asset Management disclosed on February 24, 2026, in an SEC filing that it acquired 917,670 shares of AptarGroup, valued at $111.92 million, indicating confidence in the company's future prospects.
- Ownership Proportion Analysis: This transaction represents 1.23% of River Road's 13F reportable assets under management as of December 31, 2025, suggesting that AptarGroup is no longer among the fund's top five holdings, which may affect its risk profile.
- Market Performance Review: As of February 28, 2026, AptarGroup's shares traded at $143.71, down 1.32% over the past year, underperforming the S&P 500 by 18.68 percentage points, reflecting market caution regarding its growth potential.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which may attract environmentally-conscious investors despite its current stock performance.
See More
River Road Asset Management Acquires AptarGroup Shares Worth $111.92 Million
- New Investment Position: River Road Asset Management disclosed in an SEC filing dated February 24, 2026, that it acquired 917,670 shares of AptarGroup valued at $111.92 million, marking a new investment position that reflects confidence in AptarGroup's future growth potential.
- Asset Management Proportion: This acquisition represents 1.23% of River Road's 13F reportable assets as of December 31, 2025, indicating a strategic consideration in diversifying its investment portfolio, which could enhance overall investment returns.
- Performance Growth Outlook: AptarGroup reported a 14% increase in sales in its fourth-quarter report for 2025, with all core segments showing growth, demonstrating the company's competitiveness and sustained profitability, which is likely to attract more investor interest going forward.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which appeals to environmentally conscious investors and further enhances its market attractiveness.
See More
Consumer Staples Sector Overbought Warning
- Overbought Signals: As of February 27, 2026, Darling Ingredients Inc (NYSE:DAR) and Coca-Cola Consolidated Inc (NASDAQ:COKE) are flagged as overbought stocks in the consumer staples sector, with RSI indicators exceeding 70, indicating potential price correction risks in the short term, prompting caution among investors.
- RSI Indicator Insights: The Relative Strength Index (RSI), a momentum indicator that compares the strength of stock price increases to decreases, assists traders in assessing short-term performance, and an overbought condition may lead to losses for investors buying at high levels.
- Market Reaction: The emergence of overbought signals may prompt investors to reassess the investment value of these two stocks, potentially leading to short-term capital outflows that could affect overall market sentiment and price movements.
- Investment Strategy Adjustments: Given the current overbought conditions, investors may need to adjust their strategies, considering more attractive buying opportunities during price corrections to mitigate potential risks and optimize their portfolios.
See More
